Principal Investigator |
Avi Z Rosenberg, M.D., Ph.D.
Dr. Avi Z. Rosenberg is a fellowship-trained renal/pediatric pathologist with PhD-level training as a Cell Biologist. In addition to his clinical service (reviewing over 600 biopsies/year), he runs a renal pathobiology lab studying the fundamental mechanisms of primary and adaptive forms of kidney injury, building on collaborative work exploring mechanisms of podocyte injury. The Renal Pathobiology group includes a research specialist, 4 post-doctoral fellows (2 shared with Halushka Lab) and 2 shared graduated students (Halushka Lab). Weekly try-lab data sessions for in-depth feedback and constructive criticism are also held.
|
Postdoctoral Fellows |
Parnaz Daneshpajouhnejad, M.D.
Parnaz Daneshpajouhnejad, M.D. received her medical degree from Iran, and joined Rosenberg lab in 2018. With her clinical background and her enthusiasm towards research activities, she grew interest in digging the basis of pathobiological causes of renal disorders. She is currently involved in studies focused on evaluation podocyte function and structure in both mice and human models, to assess the effects of obesity, diabetes, and aging on kidney diseases and potential interventions. |
Xiaoping Yang, M.D., Ph.D.
|
Former Members |
| Marco Delsante, M.D. (2017-2018) – Current position: Parma University Hospital, Italy
|
Xiaoping Yang, M.D., Ph.D. completed her MD training in China and received her Ph.D. degree from Kanazawa University, Japan. She joined inherited hypercholesterolemia research in National institutes of health (NHLBI) Bethesda, and then moved to Johns Hopkins University, Dr. Lewis Becker’s Lab, in the Department of Cardiology. She identified scavenge receptor B1 as a Lp(a) receptor and found chemokine CX3C and receptor CX3CR1 regulate I-CAM by JAK-STAT5 pathway. She joined Dr. Avi Rosenberg’s Lab in 2017. To date, she has used iPSC to develop kidney organoid and established an in vitro kidney fibrosis model. She is interested in the current research project and is dissecting a new drug with anti-fibrosis mechanism.